Source:http://linkedlifedata.com/resource/pubmed/id/11071261
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5A
|
| pubmed:dateCreated |
2001-2-2
|
| pubmed:abstractText |
We conducted a pilot study in 20 patients with high-risk or recurrent/refractory non-Hodgkin's lymphoma (NHL) using high-dose sequential chemotherapy (HDSC) and autologous hematopoietic cell transplantation (AHCT). After cytoreduction with standard salvage therapy, HDSC/AHCT was administered in 4 phases at 2- to 4-week intervals. Phase 1 consisted of cyclophosphamide 7 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) at 10 microg/kg per day and leukapheresis upon recovery from white blood cell nadir. The hematopoietic cell product was enriched by Percoll gradient separation and purged with a B-cell or T-cell monoclonal antibody panel and complement. Phase 2 consisted of methotrexate 8 g/m2 with leucovorin rescue and vincristine 1.4 mg/m2. Phase 3 was etoposide 2 g/m2 with G-CSF 5 microg/kg per day. In phase 4, the preparative regimen of mitoxantrone 60 mg/m2 and melphalan 180 mg/m2 was administered followed by AHCT. The NHL histologies were diffuse large cell, follicular/diffuse mixed, small noncleaved cell, T-cell-rich B-cell, lymphoblastic, and peripheral T cell. The remission status was first partial remission (PR1; n = 1) or beyond first complete remission (post-CR1; n = 19). Of the 20 patients enrolled, 11 proceeded through all 4 phases. Nine were removed from the study after the first or second phase because of progressive disease (n = 5), poor hematopoietic cell mobilization (n = 1), excessive toxicity (n = 2), and chronic active hepatitis C (n = 1). Treatment-related toxicities in the remaining 11 transplant recipients were cardiomyopathy, hemorrhagic cystitis, persistent cytopenias, acute renal failure, abnormal liver function test results, and infectious complications. There were no treatment-related deaths. Eight of the 11 transplant recipients were alive, 6 without disease, at a median follow-up of 2.7 years. The estimated median 2-year event-free survival was 55%, and overall survival was 70%. We conclude that HDSC/AHCT in refractory/recurrent NHL is associated with considerable acute and chronic toxicities. Given the toxicity profile, efficacy data were not sufficiently promising to warrant further study.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Mitoxantrone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1083-8791
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
555-62
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:11071261-Acute Kidney Injury,
pubmed-meshheading:11071261-Adult,
pubmed-meshheading:11071261-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11071261-Bone Marrow Diseases,
pubmed-meshheading:11071261-Bone Marrow Purging,
pubmed-meshheading:11071261-Cardiomyopathies,
pubmed-meshheading:11071261-Combined Modality Therapy,
pubmed-meshheading:11071261-Cyclophosphamide,
pubmed-meshheading:11071261-Cystitis,
pubmed-meshheading:11071261-Disease Progression,
pubmed-meshheading:11071261-Disease-Free Survival,
pubmed-meshheading:11071261-Drug Administration Schedule,
pubmed-meshheading:11071261-Drug-Induced Liver Injury,
pubmed-meshheading:11071261-Etoposide,
pubmed-meshheading:11071261-Female,
pubmed-meshheading:11071261-Follow-Up Studies,
pubmed-meshheading:11071261-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:11071261-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:11071261-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11071261-Hemorrhage,
pubmed-meshheading:11071261-Humans,
pubmed-meshheading:11071261-Infection,
pubmed-meshheading:11071261-Leucovorin,
pubmed-meshheading:11071261-Life Tables,
pubmed-meshheading:11071261-Lymphoma, Non-Hodgkin,
pubmed-meshheading:11071261-Male,
pubmed-meshheading:11071261-Melphalan,
pubmed-meshheading:11071261-Methotrexate,
pubmed-meshheading:11071261-Middle Aged,
pubmed-meshheading:11071261-Mitoxantrone,
pubmed-meshheading:11071261-Pilot Projects,
pubmed-meshheading:11071261-Salvage Therapy,
pubmed-meshheading:11071261-Survival Analysis,
pubmed-meshheading:11071261-Survival Rate,
pubmed-meshheading:11071261-Transplantation, Autologous,
pubmed-meshheading:11071261-Transplantation Conditioning,
pubmed-meshheading:11071261-Treatment Outcome,
pubmed-meshheading:11071261-Vincristine
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Division of Bone Marrow Transplantation, Stanford University, California 94305, USA. laura.johnston@stanford.edu
|
| pubmed:publicationType |
Journal Article
|